Implementing evidence-based behavioural modifications can create an internal environment that supports incretin hormone activity and metabolic health
The short answer: Yes, but usually mild and rare when taken at recommended doses
However, it is crucial to note that current evidence does not support the use of GLP-1RAs for the primary treatment of HFrEF
Miamis Double Board-Certified MD breaks down Miami peptide therapy, GLP-1 injections, side effects, and how to use them safely
Stacking MOTS-C with any of these makes sense when a patient is dealing with both a metabolic goal (fat loss, energy) and a tissue or immune issue (gut healing, joint recovery, post-illness rebuilding)
Injectable options such as semaglutide and tirzepatide are commonly self-administered at home using a pre-filled pen, while oral GLP-1 medications are taken once daily